239 related articles for article (PubMed ID: 2455359)
1. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost).
Pedvis LG; Wong T; Frojmovic MM
Thromb Haemost; 1988 Apr; 59(2):323-8. PubMed ID: 2455359
[TBL] [Abstract][Full Text] [Related]
2. Control of human and animal platelet aggregation by a new prostacyclin analog.
Maderna P; Colli S; Sirtori C; Tremoli E; Paoletti R
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():363-9. PubMed ID: 2408447
[TBL] [Abstract][Full Text] [Related]
3. Platelet sensitivity in vitro to the prostacyclin analogue iloprost in diabetic patients.
Vicari AM; Macagni A; Pozza G
Horm Metab Res; 1989 Nov; 21(11):616-8. PubMed ID: 2480323
[TBL] [Abstract][Full Text] [Related]
4. Adrenaline and adenosine diphosphate-induced platelet aggregation require shape change. Importance of pseudopods.
Milton JG; Frojmovic MM
J Lab Clin Med; 1984 Nov; 104(5):805-15. PubMed ID: 6387013
[TBL] [Abstract][Full Text] [Related]
5. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
6. Platelet size affects both micro- and macro-aggregation: contributions of platelet number, volume fraction and cell surface.
Wong T; Pedvis L; Frojmovic M
Thromb Haemost; 1989 Sep; 62(2):733-41. PubMed ID: 2683192
[TBL] [Abstract][Full Text] [Related]
7. Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man.
Cowley AJ; Heptinstall S; Hampton JR
Thromb Haemost; 1985 Feb; 53(1):90-4. PubMed ID: 2581332
[TBL] [Abstract][Full Text] [Related]
8. Changes in some aspects of platelet function with improvement of glycaemic control over 6 months.
Collier A; Tymkewycz PM; Matthews DM; Jones RL; Clarke BF
Diabetes Res; 1987 Jun; 5(2):79-82. PubMed ID: 2443296
[TBL] [Abstract][Full Text] [Related]
9. Effect of Iloprost (ZK 36 374), a novel prostacyclin analogue, on ADP-induced platelet aggregation.
Wadenvik H; Kutti J
Acta Haematol; 1985; 73(4):224-7. PubMed ID: 2414956
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.
Mardla V; Kobzar G; Samel N
Platelets; 2004 Aug; 15(5):319-24. PubMed ID: 15370103
[TBL] [Abstract][Full Text] [Related]
11. The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood.
Saniabadi AR; Lowe GD; Belch JJ; Forbes CD; Prentice CR; Barbenel JC
Thromb Haemost; 1983 Oct; 50(3):718-21. PubMed ID: 6196854
[TBL] [Abstract][Full Text] [Related]
12. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C
Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976
[TBL] [Abstract][Full Text] [Related]
13. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD
Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ADP-induced responses in human platelets by agents elevating the cyclic AMP level: comparison of aggregation and shape change.
Steen VM; Holmsen H
Thromb Haemost; 1984 Dec; 52(3):333-5. PubMed ID: 6099615
[TBL] [Abstract][Full Text] [Related]
15. Critical evaluation of the in vivo selectivity between hypotensive and platelet antiaggregating actions of iloprost and prostacyclin in beagle dogs.
Hermán F; Hadházy P; Magyar K
Arch Int Pharmacodyn Ther; 1989; 300():281-91. PubMed ID: 2482710
[TBL] [Abstract][Full Text] [Related]
16. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
[TBL] [Abstract][Full Text] [Related]
17. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
18. Microscopic measurements of platelet aggregation reveal a low ADP-dependent process distinct from turbidometrically measured aggregation.
Frojmovic MM; Milton JG; Duchastel A
J Lab Clin Med; 1983 Jun; 101(6):964-76. PubMed ID: 6406629
[TBL] [Abstract][Full Text] [Related]
19. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
Michel G; Seipp U
Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide and prostacyclin modulate the alterations in cardiac action potential duration mediated by platelets during ischaemia.
Goulielmos NV; Enayat ZE; Sheridan DJ; Cohen H; Flores NA
Cardiovasc Res; 1995 Nov; 30(5):788-98. PubMed ID: 8595628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
